Vaxcyte, Inc. — Director's Dealing 2022

Mar 24, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2022-03-22

Reporting Person: Sauer Paul (SVP Process Dev, Manufacturing)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-22	Common Stock	S	3000	$25.00	Disposed	28125	Direct

Footnotes

F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.